Kutkin

Compound Class	Kutkin is an iridoid glycoside mixture, not a single molecule — no single CAS applies
Composition	Picroside I and kutkoside in an approximate 1:1.5 ratio; the standardised fraction is also known as picroliv
Botanical Source	Picrorhiza kurroa (kutki; katuka) — a Himalayan alpine species
Plant Part(s)	Root and rhizome (typically 3–4 years old)
Typical Standardisation	Kutkin by HPLC; 4–10% commercial range. Picrosides I and II may be co-specified
Primary Applications	Hepatoprotective formulation; bitter digestive tonic; cholagogue
Claim Strength (Overview)	Moderate — strong preclinical hepatoprotection with efficacy comparable to silymarin; human trial data is limited but real
Buy from Herbuno	Kutkin 10% Powder (Kutki Extract) | Standardized Picrorhiza kurroa → Kutkin 4% Powder (Kutki Extract) | Standardized Picrorhiza kurroa →

Name origin: Kutkin takes its name from kutki, the Hindi common name for the plant, itself connected to the Sanskrit katuka, meaning bitter or pungent — a direct reference to the root’s intense bitterness. The genus name Picrorhiza is Greek for "bitter root," making this one of the few compounds in this index whose botanical and vernacular names converge on the same sensory fact. The standardised fraction is also marketed as picroliv. Traditional use: Picrorhiza kurroa is a cornerstone Ayurvedic hepatic and bitter-tonic herb, prescribed for jaundice, fever, and disorders of digestion and the liver, and classified among the bitters used to stimulate appetite and bile flow. Its traditional hepatic indication is one of the more precisely vindicated in the Ayurvedic pharmacopoeia, with modern pharmacology converging on the same organ system rather than reinterpreting the herb into an unrelated application. Research trajectory: Kutkin research was driven substantially by Indian pharmaceutical work from the 1980s onward, notably at the Central Drug Research Institute, which characterised picroliv and tested it head-to-head against silymarin in rodent hepatotoxicity models. This produced an unusual and commercially relevant result: the Indian botanical performed comparably to the European reference standard. Commercial source: Picrorhiza kurroa root and rhizome extract standardized to kutkin content. The species is Himalayan alpine, slow-growing, and endangered — conservation-sourcing due diligence is a material, not decorative, requirement for this ingredient.

---

Evidence for Kutkin Applications

The defining fact about kutkin is that it is a mixture, not a molecule, and its composition is precisely defined. Picroliv — the standardised active fraction, also called kutkin — is an iridoid glycoside mixture containing 60% picroside I and kutkoside in a ratio of 1:1.5, obtained from three-to-four-year-old roots and rhizomes; critically, it has shown efficacy comparable to silymarin in rodent models of galactosamine-, paracetamol-, thioacetamide-, and carbon-tetrachloride-induced hepatic damage, and has also demonstrated choleretic and anti-cholestatic effects (Dwivedi 2009). Head-to-head comparability with silymarin across four independent hepatotoxin models is a substantive preclinical result. Claim strength: Moderate.

The mechanism has been characterised with reasonable specificity rather than left as generic "antioxidant" hand-waving. In adult male albino rats, pretreatment with picroliv prevented the hepatotoxic effects of paracetamol and galactosamine as evidenced by biochemical and histopathological measures, with maximum hepatoprotective effect at daily oral doses of 6 and 12 mg/kg for seven to eight days; the antihepatotoxic action appears to derive from an alteration in the biotransformation of toxic substances, resulting in decreased formation of reactive metabolites (Dwivedi 1991). That is a metabolic-interception mechanism, not merely radical scavenging — and it is mechanistically well matched to a prophylactic rather than therapeutic use pattern. Claim strength: Moderate (mechanistic).

Human evidence exists but is thin and dated, and honesty requires saying so. A randomised, double-blind, placebo-controlled trial in patients with acute viral hepatitis administered Picrorhiza kurroa root powder at 375 mg three times daily for two weeks against matching placebo, reporting significant differences in bilirubin, SGOT, and SGPT between groups. This is a genuine controlled trial with a positive result, but it is small, decades old, and has not been replicated at scale. The gap between the strength of the preclinical literature and the thinness of the human literature is the honest headline for this compound. Claim strength: Emerging to Moderate.

An instructive pharmacological observation from the literature deserves flagging because it cuts against a common assumption: glycosides in alcoholic extracts have been reported as more effective than pure isolated compounds in treating liver ailments — that is, the mixture appears to outperform its purified constituents. This is precisely why the standardised fraction is defined as a picroside I / kutkoside combination at a specified ratio rather than as a single purified molecule, and it is a caution against the reflexive assumption that a higher-purity isolate is a better ingredient. Claim strength: Moderate.

Beyond hepatoprotection, picroliv has shown antiviral and immunostimulant activity in preclinical work and protective effects against chemically induced carcinogenesis in rodent models, and has been reported as devoid of significant toxicity in those studies. Additional work has demonstrated hepatoprotective and renal-protective activity against cadmium-induced injury. These are genuine preclinical findings but should not be extended into human claims, and the immunostimulant activity in particular warrants the same caution flagged elsewhere in this index for immune-modulating botanicals. Claim strength: Emerging.

---

Dosage & Formulator Specification

Herbuno carries Picrorhiza kurroa root extract standardized to 10% and 4% kutkin by HPLC, alongside unstandardized kutki extract powder, organic whole root powder, and water-soluble and oil-soluble extracts. For applications resting on the hepatoprotective literature, the standardized grades are the appropriate material, as the trial and preclinical work used defined picroside/kutkoside content.

The human trial cited above used Picrorhiza kurroa root powder at 375 mg three times daily (1,125 mg/day of whole root powder) for two weeks — a whole-root rather than standardized-extract dose, which formulators must convert carefully rather than applying directly to a 10% kutkin extract. Preclinical picroliv dosing at maximum effect was 6–12 mg/kg/day of the standardized fraction. As with silymarin, the mechanism (interception of toxic metabolite formation) is better matched to prophylactic co-administration alongside a hepatotoxic exposure than to treatment of established damage, and dosing patterns should reflect that.

Analytical verification should specify kutkin content by HPLC with picroside I and kutkoside quantified separately, since the standardised fraction is defined by their ratio (approximately 1:1.5) and not merely by their sum — two extracts with identical total kutkin can differ in this ratio. Picroside II is frequently co-specified and is a useful additional marker. Root age matters: the pharmacological literature specifies three-to-four-year-old roots and rhizomes, and younger material may not deliver the expected glycoside profile.

Picrorhiza kurroa is generally well tolerated, and the preclinical literature describes picroliv as devoid of significant toxicity; the intense bitterness is the principal practical constraint on palatability rather than any safety concern, and encapsulation is the standard solution. The overriding non-clinical caution for this ingredient is conservation: P. kurroa is a slow-growing Himalayan alpine species listed as endangered, subject to heavy wild-harvest pressure, and its trade is regulated. Documented cultivated or legally-sourced provenance is a material compliance and ethical requirement, not an optional credential, and buyers should require it. Standard caution regarding use in pregnancy is appropriate given limited data.

---

Frequently Asked Questions — Kutkin

Is kutkin a single compound?
No — it is an iridoid glycoside mixture, and this matters. The standardised fraction (also called picroliv) contains picroside I and kutkoside in an approximate 1:1.5 ratio. Notably, the literature reports that the mixture in alcoholic extracts outperforms purified single compounds for liver ailments, which is a caution against assuming a higher-purity isolate is a better ingredient.

How does kutkin compare to silymarin?
Favourably, at least preclinically. Picroliv showed efficacy comparable to silymarin across four independent rodent hepatotoxicity models — galactosamine, paracetamol, thioacetamide, and carbon tetrachloride. That said, the human evidence for kutkin is considerably thinner than for silymarin, resting largely on one small, dated but genuinely controlled trial in acute viral hepatitis.

How does kutkin protect the liver?
Not simply by radical scavenging. The mechanism appears to be metabolic interception — altering the biotransformation of toxic substances so that fewer reactive metabolites form in the first place. This is mechanistically better matched to prophylactic co-administration alongside a hepatotoxic exposure than to treating established liver damage.

Are there sourcing concerns with Picrorhiza kurroa?
Yes, and they are material. It is a slow-growing Himalayan alpine species listed as endangered, under heavy wild-harvest pressure, with regulated trade. Documented cultivated or legally-sourced provenance is a compliance and ethical requirement, not an optional credential. Root age also matters — the pharmacology specifies 3-4 year old roots.

Related compounds: Silymarin, Silybin, Andrographolide, Berberine

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery